We are live on ! Find out more
VM

VV Manager Portfolio holdings

AUM $114M
1-Year Est. Return 59.16%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
+59.16%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$126M
AUM Growth
-$8.9M
Cap. Flow
-$16.1M
Cap. Flow %
-12.81%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
OYST
Oyster Point Pharma, Inc. Common Stock
OYST
+$16.9M

Top Sells

Rank Stock Value
1
ALLO icon
Allogene Therapeutics
ALLO
+$33M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLO icon
1
Allogene Therapeutics
ALLO
$625M
$75.1M 59.81%
2,889,651
-1,197,870
-29% -$33M
OYST
2
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$23.5M 18.76%
+963,468
New +$16.9M
QTTB icon
3
Q32 Bio
QTTB
$345M
$16M 12.71%
42,825
– –
STRO icon
4
Sutro Biopharma
STRO
$382M
$11M 8.72%
99,558
– –

Similar funds

MCM
Maxim Capital Management San Francisco, California $112M AUM 0.1% 1-Year Est. Return
GTP
Global Thematic Partners New York $120M AUM 25.18% 1-Year Est. Return
APG
Andrew P. Goldfarb $102M AUM 9.91% 1-Year Est. Return
LM
Legg Mason Baltimore, Maryland $127M AUM 6.76% 1-Year Est. Return
VPMV
Venrock Partners Management V Palo Alto, California $101M AUM
CCM
Castine Capital Management Boston, Massachusetts $129M AUM 23.45% 1-Year Est. Return
CCM
Cloverdale Capital Management Dallas, Texas $135M AUM 13.89% 1-Year Est. Return
BWM
Bernicke Wealth Management Altoona, Wisconsin $135M AUM 4.61% 1-Year Est. Return

VV Manager's Q4 2019 Portfolio in Review

As of Q4 2019, VV Manager held 4 positions worth $126M, down 6.6% from $134M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

VV Manager withdrew a net $16.1M in Q4 2019, reducing 1 holding. Its largest reduction was Allogene Therapeutics, cutting an estimated $33M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, VV Manager opened a new position in Oyster Point Pharma, Inc. Common Stock worth $23.5M.

  • VV Manager's largest Q4 2019 buy was Oyster Point Pharma, Inc. Common Stock: 963,468 shares worth $23.5M.
  • VV Manager's biggest Q4 2019 reduction was Allogene Therapeutics, cutting an estimated $33M.
  • VV Manager's ten largest holdings make up 100% of its $126M portfolio in Q4 2019.
  • VV Manager opened 1 new position and closed 0 in Q4 2019.
  • VV Manager's portfolio value fell 6.6% quarter-over-quarter to $126M.

Based on VV Manager's 13F filing for Q4 2019, filed 8 Jan 2020.